How snake venom disintegrins affect platelet aggregation and cancer proliferation

Kolvekar, Nivedita; Bhattacharya, Navodipa; Sarkar, Angshuman; Chakrabarty, Dibakar

doi:10.1016/j.toxicon.2022.106982

Cited by 8 publications

(9 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 3 shows the intracellular reactions that take place when disintegrins bind to integrin targets, as illustrated in the current literature. The involvement of α5β1-, αVβ3-, α1β1-, α2β1-, α4β1-, and α5β1-integrins in survival, proliferation, infiltration, motility, cytoskeletal reorganization, angiogenesis, apoptosis, and interaction with snake venom disintegrins triggers the onset of these mechanisms in cancer cells [ 81 ].…”

Section: Potential Applications Of Svd In Angiogenesis-related Diseasesmentioning

confidence: 99%

“…Each individual platelet is equipped with approximately 80,000 GPIIbIIIa receptors located both on the plasma membrane and in the α-granules [ 108 ]. After activation, the number of these receptors increases significantly, facilitating the formation of a permanent hemostatic plug [ 81 ]. Certain SVDs, including those of Agkistrodon piscivorus piscivorus and Echis carinatus sochureki , namely, Applagin and Echistatin, show remarkable affinity for the RGD motif on resting platelets.…”

Section: Utilization Of Svd As Pro-angiogenic Agentsmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Snake Venom Disintegrins in Angiogenesis

Clissa,

Della-Casa,

Zychar

et al. 2024

Toxins

View full text Add to dashboard Cite

Angiogenesis, the formation of new blood vessels, plays a critical role in various physiological and pathological conditions. Snake venom disintegrins (SVDs) have been identified as significant regulators of this process. In this review, we explore the dual roles of SVD in angiogenesis, both as antiangiogenic agents by inhibiting integrin binding and interfering with vascular endothelial growth factors and as proangiogenic agents by enhancing integrin binding, stimulating cell migration and proliferation, and inducing neoangiogenesis. Studies in vitro and in animal models have demonstrated these effects and offer significant therapeutic opportunities. The potential applications of SVD in diseases related to angiogenesis, such as cancer, ocular diseases, tissue regeneration, wound healing, and cardiovascular diseases, are also discussed. Overall, SVDs are promising potential therapeutics, and further advances in this field could lead to innovative treatments for diseases related to angiogenesis.

show abstract

Section: Potential Applications Of Svd In Angiogenesis-related Diseasesmentioning

confidence: 99%

Section: Utilization Of Svd As Pro-angiogenic Agentsmentioning

confidence: 99%

The Role of Snake Venom Disintegrins in Angiogenesis

Clissa,

Della-Casa,

Zychar

et al. 2024

Toxins

View full text Add to dashboard Cite

show abstract

“…Abbreviations: 3FTx, three‐finger toxin; DIS, disintegrin; LAAO, L‐amino acid oxidase; PLA 2 , phospholipase A2. Adapted from Hiu and Yap (2020), Kalita et al (2021) and Kolvekar et al (2023).…”

Section: Anticancer Effects Of Individual Snake Venom Toxinsmentioning

confidence: 99%

“…Some 3FTx (e.g., rCT3) can induce both intrinsic and extrinsic apoptotic pathways as demonstrated by PLA2 and LAAO toxins (Derakhshani et al, 2020). Another toxin, DIS, interacts with integrins and disrupts cancer cells adhesion, invasion, migration, angiogenesis and actin cytoskeletal reorganisation by inhibiting several pathways through focal adhesion kinases (FAK) (Kolvekar et al, 2023). Also, DIS regulates integrin‐dependent apoptosis through upregulation of pro‐apoptotic proteins and downregulation of anti‐apoptotic proteins (Hammouda et al, 2016).…”

Section: Anticancer Effects Of Individual Snake Venom Toxinsmentioning

confidence: 99%

Snake venom toxins: Potential anticancer therapeutics

Offor,

Piater

2023

J of Applied Toxicology

View full text Add to dashboard Cite

Snake venom contains a cocktail of compounds dominated by proteins and peptides, which make up the toxin. The toxin components of snake venom attack several targets in the human body including the neuromuscular system, kidney and blood coagulation system and cause pathologies. As such, the venom toxins can be managed and used for the treatment of these diseases. In this regard, Captopril used in the treatment of cardiovascular diseases was the first animal venom toxin‐based drug approved by the US Food and Drug Administration and the European Medicines Agency. Cancers cause morbidity and mortality worldwide. Due to side effects associated with the current cancer treatments including chemotherapy, radiotherapy, immunotherapy, hormonal therapy and surgery, there is a need to improve the efficacy of current treatments and/or develop novel drugs from natural sources including animal toxin‐based drugs. There is a long history of earlier and ongoing studies implicating snake venom toxins as potential anticancer therapies. Here, we review the role of crude snake venoms and toxins including phospholipase A2, L‐amino acid oxidase, C‐type lectin and disintegrin as potential anticancer agents tested in cancer cell lines and animal tumour models in comparison to normal cell lines. Some of the anti‐tumour activities of snake venom toxins include induction of cytotoxicity, apoptosis, cell cycle arrest and inhibition of metastasis, angiogenesis and tumour growth. We thus propose the advancement of multidisciplinary approaches to more pre‐clinical and clinical studies for enhanced bioavailability and targeted delivery of snake venom toxin‐based anticancer drugs.

show abstract

“…The binding of PAC-1 antibody is competitively inhibited by RGD-containing peptides, and thus the PAC-1-FITC antibody can be employed in flow cytometry to quantify disintegrin binding to GPIIb-IIIa( Figure 4 d). However, some venom disintegrins do not bind the GPIIb-IIIa integrin and therefore require alternative assays for their specific integrin targets, such as fibroblast cell migration assays [ 62 ].…”

Section: The Eu-funded Addovenom Projectmentioning

confidence: 99%

ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite Envenoming

Menzies,

Arinto-Garcia,

Amorim

et al. 2023

Toxins

View full text Add to dashboard Cite

Snakebite envenoming can be a life-threatening medical emergency that requires prompt medical intervention to neutralise the effects of venom toxins. Each year up to 138,000 people die from snakebites and threefold more victims suffer life-altering disabilities. The current treatment of snakebite relies solely on antivenom—polyclonal antibodies isolated from the plasma of hyperimmunised animals—which is associated with numerous deficiencies. The ADDovenom project seeks to deliver a novel snakebite therapy, through the use of an innovative protein-based scaffold as a next-generation antivenom. The ADDomer is a megadalton-sized, thermostable synthetic nanoparticle derived from the adenovirus penton base protein; it has 60 high-avidity binding sites to neutralise venom toxins. Here, we outline our experimental strategies to achieve this goal using state-of-the-art protein engineering, expression technology and mass spectrometry, as well as in vitro and in vivo venom neutralisation assays. We anticipate that the approaches described here will produce antivenom with unparalleled efficacy, safety and affordability.

show abstract

How snake venom disintegrins affect platelet aggregation and cancer proliferation

Cited by 8 publications

References 149 publications

The Role of Snake Venom Disintegrins in Angiogenesis

The Role of Snake Venom Disintegrins in Angiogenesis

Snake venom toxins: Potential anticancer therapeutics

ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite Envenoming

Contact Info

Product

Resources

About